Key result
The ACE gene insertion/deletion polymorphism was not associated with an increased risk of venous thromboembolism (OR 0.97; 95% CI 0.81-1.16).
Why the study?
Is the angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism associated with an increased risk of venous thromboembolism?
Population
995 individuals, comprising 517 unselected patients with venous thromboembolism and 478 blood donors
Comparison
Angiotensin-converting enzyme gene… vs Control group (blood donors without VTE)
Design
Case-control
Authors
Loading...
Does not support ACE genotyping for VTE risk assessment; leaves open associations in selected subgroups or other thrombotic phenotypes.
Case-Control (n=995)
Is the angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism associated with an increased risk of venous thromboembolism?
Odds Ratio: 0.97 (95% CI 0.81–1.16)
Absolute Event Rate: 0.53% vs 0.54%
The ACE gene I/D polymorphism is not a significant risk factor for venous thromboembolism in unselected patients.
Jackson et al. (2000) conducted a case-control in venous thromboembolism (n=995). ACE gene insertion/deletion (I/D) polymorphism vs. Controls (blood donors) was evaluated on Venous thromboembolism (OR 0.97, 95% CI 0.81-1.16). The ACE gene insertion/deletion polymorphism was not associated with an increased risk of venous thromboembolism (OR 0.97; 95% CI 0.81-1.16).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: